TD Cowen raises Ascendis Pharma stock price target on revenue beat

TD Cowen raised its price target for Ascendis Pharma (ASND) to $352, citing strong Q3 revenue beats across its products. Revenue grew 86% YoY with a 92% gross margin. The company reaffirmed long-term revenue targets of €5B by 2030 and €10B by 2035. ASND stock trades near its 52-week high at $266.31. Other analysts also raised targets and maintained positive ratings.

Original reporting
Published Nov 13, 2026, 2:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 2:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ASND
Bullish
high confidence
Mentioned
$ASND
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ASNDBullishMed
01

Why it matters

The earnings beat and target upgrades create a bullish catalyst, but the stock remains near its 52‑week high, suggesting limited upside room.

02

Market read

Earnings beat and analyst upgrades provide a fresh, material catalyst for ASND, offering a medium‑term buying opportunity.

03

What to watch

Potential regulatory or clinical trial setbacks could offset the short‑term earnings momentum.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Ascendis Pharma (NASDAQ:ASND) reported Q3 2026 results that beat consensus, prompting several analysts to raise price targets.

Company-level read

Ticker impact

$ASNDBullishHigh confidence
Context

Q3 2026 earnings beat estimates and multiple analysts raised price targets, indicating fresh positive fundamentals.

Expected impact

likely upward pressure as the market prices in the earnings beat and higher targets

Evidence & confidence

Earnings beat, revenue growth, and raised price targets from TD Cowen, Wells Fargo and Raymond James provide a concrete catalyst for buying interest.

Market effects

Biotech and rare‑disease sector may see broader optimism from the earnings beat.

U.S. biotech investors likely to react positively; European markets less affected.

Limited to investors tracking biotech earnings; no macro‑level impact.

Counterpoint

The stock may already be priced in; further upside could be limited if guidance falls short of long‑term targets.

Key entities

  • TD Cowen

    Raised price target to $352 and maintained Buy rating.

  • Wells Fargo

    Raised price target to $330, maintaining Overweight.

  • Raymond James

    Reiterated Outperform rating after earnings beat.

Related articles

$ASNDMedAI 8/10

Ascendis Pharma AS (ASND) Q3 2026 Earnings Call Highlights: Revenue Surges 89% as YORVIPATH

Ascendis Pharma AS reported Q3 2026 revenue up 89%, driven by YORVIPATH. CEO Jan Mikkelsen discussed new therapeutic areas, ex-US growth, and YUVIWEL's potential. The company expects steady US uptake and EUR5B 2030 sales. CFO Scott Smith noted EUR330M spent on share buybacks, with EUR600M operating cash flow guided for 2026. Margins improved to mid-40s, with no major commercial infrastructure changes expected.

$ASNDHighAI 8/10

Ascendis Pharma earnings analysis: questions answered and next catalysts

Ascendis Pharma (ASND) reported Q3 2026 earnings, beating revenue and EPS estimates. Shares rose 2.93% to $266.88. Key drugs showed strong demand, and the company increased its cash flow outlook. Management addressed growth, funding, and competition. Next catalysts include regulatory decisions, clinical trials, and market expansion. Analysts debate valuation and future growth prospects.

$ASNDHighAI 8/10

Ascendis (ASND) Q3 2026 Earnings Call Transcript

Ascendis (ASND) reported Q3 2026 product revenue of €366 million, up 89% YoY. Key drivers: growth in existing products (Yorvipath, Yuvivel, Skytrofa), indication expansions, and new products. Yorvipath revenue was €291 million, up 103% YoY. Yuvivel and Skytrofa also showed strong demand. The company aims for €5 billion in annual revenue by 2030.

HighAI 8/10

Why is Ascendis Pharma stock climbing today?

Ascendis Pharma's stock rose 0.5% in pre-market trading after its Q3 2026 earnings beat estimates, with adjusted EPS of €1.08 vs. €0.80 and revenue of €369.7M vs. €363.0M. YORVIPATH sales grew 103% YoY to €291M. The company also repurchased 2M shares for $459M and received positive EU regulatory opinions for TransCon CNP.